Juluca is owned by Viiv Hlthcare.
Juluca contains Dolutegravir Sodium; Rilpivirine Hydrochloride.
Juluca has a total of 6 drug patents out of which 1 drug patent has expired.
Expired drug patents of Juluca are:
Juluca was authorised for market use on 21 November, 2017.
Juluca is available in tablet;oral dosage forms.
Juluca can be used as treatment of hiv infection.
The generics of Juluca are possible to be released after 24 January, 2031.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|US8080551||VIIV HLTHCARE||HIV inhibiting pyrimidines derivatives|| |
(2 months from now)
|US7125879||VIIV HLTHCARE||HIV inhibiting pyrimidines derivatives|| |
(2 years from now)
|US8129385||VIIV HLTHCARE||Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness|| |
(4 years from now)
|US9242986||VIIV HLTHCARE||Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates|| |
(6 years from now)
|US10426780||VIIV HLTHCARE||Antiviral therapy|| |
(7 years from now)
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8101629||VIIV HLTHCARE||Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile|| |
(5 months ago)
Market Authorisation Date: 21 November, 2017
Treatment: Treatment of hiv infection
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic